Immunotherapies Targeting Tumor-Associated Macrophages (TAMs) in Cancer
Pharmaceutics · 27.06.2024 · 16 (7) · 865
DOI: 10.3390/pharmaceutics16070865 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 27.06.2024. Verfasst von Mei-Ye Li und 2 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 194 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Shenzhen Longhua District Science and Technology Innovation Fund, Open Project of Scientific Research Workstation of the Chinese Disease Control Journal.
Abstract (Originalsprache)
Tumor-associated macrophages (TAMs) are one of the most plentiful immune compositions in the tumor microenvironment, which are further divided into anti-tumor M1 subtype and pro-tumor M2 subtype. Recent findings found that TAMs play a vital function in the regulation and progression of tumorigenesis. Moreover, TAMs promote tumor vascularization, and support the survival of tumor cells, causing an impact on tumor growth and patient prognosis. Numerous studies show that reducing the density of TAMs, or modulating the polarization of TAMs, can inhibit tumor growth, indicating that TAMs are a promising target for tumor immunotherapy. Recently, clinical trials have found that treatments targeting TAMs have achieved encouraging results, and the U.S. Food and Drug Administration has approved a number of drugs for use in cancer treatment. In this review, we summarize the origin, polarization, and function of TAMs, and emphasize the therapeutic strategies targeting TAMs in cancer treatment in clinical studies and scientific research, which demonstrate a broad prospect of TAMs-targeted therapies in tumor immunotherapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.
- People's Hospital of Longhua, The affiliated hospital of Southern Medical University, Shenzhen 518109, China.
Förderung
- National Natural Science Foundation of China
- Shenzhen Longhua District Science and Technology Innovation Fund
- Open Project of Scientific Research Workstation of the Chinese Disease Control Journal
Zitieren
APA
Li, M. Y., Ye, W., & Luo, K. W. (2024). Immunotherapies Targeting Tumor-Associated Macrophages (TAMs) in Cancer. Pharmaceutics, 16(7), 865. https://doi.org/10.3390/pharmaceutics16070865
Vancouver
Li MY, Ye W, Luo KW. Immunotherapies Targeting Tumor-Associated Macrophages (TAMs) in Cancer. Pharmaceutics. 2024;16(7):865. doi:10.3390/pharmaceutics16070865
BibTeX
@article{Li2024,
author = {Li, Mei-Ye and Ye, Wei and Luo, Ke-Wang},
title = {Immunotherapies Targeting Tumor-Associated Macrophages (TAMs) in Cancer},
journal = {Pharmaceutics},
year = {2024},
volume = {16},
number = {7},
pages = {865},
doi = {10.3390/pharmaceutics16070865}
}
EUVIMED